Clinical Trial Update: Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum [Phase 4]

View source ↗

Summary

Phase 4 trial update on Ricovir in maintaining viral suppression in chronic hepatitis B patients previously treated with Viread, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Ricovir
• Viread (tenofovir disoproxil fumarate)

Snippet

Sponsor: Mylan (Taiwan) Ltd | Conditions: Chronic Hepatitis B Infection | Phase 4 | Status: COMPLETED